Mallinckrodt has sold its portfolio of intrathecal spasticity and pain management drugs to Piramal’s Critical Care subsidiary in the UK for $171 million and up to an additional $32 million payable depending on financial performance of the acquired assets over the next 3 years. The portfolio acquired includes Gablofen (baclofen), a severe spasticity management product, which is currently marketed in the U.S., and two pain management products, which are currently under development. Gablofen has...